Specifications tableSubjectCardiology and Cardiovascular MedicineSpecific subject areaInterventional Cardiology, Congenital Heart Disease, Neonatology, Morbidity and MortalityType of dataTable, FigureHow data were acquiredClinicians' analysis recording single centre registriesData formatRAWParameters for data collectionSample: Interventional cardiac catheterizations in neonatal age\
Parameters: centre, sex gender, weight, age, prematurity, co-morbidity, genetic syndrome, congenital heart disease, interventional procedure, hybrid approach, procedure failure, adverse events, mortality, blood transfusionDescription of data collectionRetrospective collection by analysing the procedural registry of each centre. No experimental features were used or applied to data collection and analysis.Data source locationBologna, Genoa, Massa, Milan, Naples, Padua, Rome, Turin (Italy)Data accessibilityIn the ARTICLE as well as in the SUPPLEMENTARY FILE sectionRelated research article**Interventional Cardiac Catheterization in Neonatal Age: Results in a Multicentre Italian Experience**\
Giordano M, Santoro G, Agnoletti G, Carminati M, Donti A, Guccione P, Marasini M, Milanesi O, Castaldi B, Cheli M, Formigari R, Gaio G, Giugno L, Lunardini A, Pepino C, Russo MG, Spadoni I\
*Int J Cardiol* 2020; PII: S0167-5273(20)30384-3; DOI: 10.1016/j.ijcard.2020.04.013 (In press)

Value of the data {#sec0001a}
=================

•Interventional cardiac catheterization is an increasing approach to treat newborns with critical congenital heart disease. No data about risk stratification of interventional procedures in this subset of patients are so far reported in literature. Our dataset aims to evaluate the intrinsic risk of trans-catheter interventional approach as well as the potential risk factors involved in any individual procedure performed at this age.•The nationwide cohort dataset recently published in the related research article provides specific information on morbidity and mortality of newborns submitted to interventional cardiac catheterization. The Authors showed that the morbidity (major adverse events and procedural failure) is significantly related to the complexity of the intended procedure while the in-hospital mortality significantly depends on the clinical characteristics and hemodynamic stability of the patient. These data may be useful to cardiologists involved in the management of newborns affected by congenital heart disease to clearly understand patient\'s risk profile of any interventional procedure.•The safety and effectiveness data of trans-catheter approach reported in this Data in Brief paper and its related research article may hopefully promote further developments in trans-catheter treatment of neonates with critical congenital heart disease. "Ad hoc"-planned future researches aiming to specifically compare percutaneous and surgical approaches in this subset of patients will give further useful information to set the future guide-lines of management of critical, neonatal-onset cardiac malformations.•Defining careful risk profile of newborns in whom an interventional cardiac catheterization is planned allows to improve pre-procedure counselling with parents and care-givers as well as gives further insights about the short-term prognosis of these frail patients. These data will hopefully improve timing and type of interventional approach (percutaneous vs surgical vs hybrid) in this frail subset of patients.

1. Data Description {#sec0001}
===================

This dataset (see also the SUPPPLEMENTARY FILE section) gives relevant details and explanations about the enrolled population/procedures (catheterizations/procedures and adverse events) and statistical analysis techniques (mainly multi-variable analysis). These data are expressed as figures and tables as well as in form of RAW DATA in the SUPPPLEMENTARY FILE section:-the [Table 1](#tbl0001){ref-type="table"} describes the different catheterization sessions and interventional procedures performed in our cohortTable 1Summary catheterizations and proceduresTable 1Interventional catheterizationN (%)Interventional procedureN (%)**Total catheterizations1551,00Total procedures1615,00**Rashkind665 (42.9)Rashkind692 (42.8)BPV335 (21.6)BPV354 (21.9)AD stent169 (10.9)AD stent211 (13.1)BAV130 (8.4)BAV135 (18.4)APV Perforation114 (7.4)APV Perforation126 (18.2)RVOT stent16 (1.0)RVOT stent16 (1.0)IVC/SVC PTA10 (0.6)IVC/SVC PTA11 (0.7)MAPCAs embolization7 (0.5)IAS Perforation9 (0.6)RPA/LPA PTA6 (0.4)IAS stent9 (0.6)Surgical Shunt stent6 (0.4)MAPCAs embolization8 (0.5)Aorta PTA5 (0.3)RPA/LPA PTA8 (0.5)AD embolization5 (0.3)Aorta PTA7 (0.4)IAS Perforation5 (0.3)Surgical Shunt stent6 (0.4)RPA/LPA stent5 (0.3)AD embolization6 (0.4)Thrombolysis3 (0.2)RPA/LPA stent6 (0.4)IAS stent2 (0.1)Thrombolysis3 (0.2)Surgical Shunt PTA2 (0.1)Surgical Shunt PTA2 (0.1)AD stent PTA2 (0.1)AD stent PTA2 (0.1)PV PTA1 (\<0.1)PV PTA1 (\<0.1)Aorta stent1 (\<0.1)Aorta stent1 (\<0.1)Femoral artery stent1 (\<0.1)Femoral artery stent1 (\<0.1)AD stent + Rashkind14 (0.9)BTV1 (\<0.1)BPV + AD stent12 (0.7)APV perf + AD stent7 (0.5)APV perf + Rashkind4 (0.3)IAS Perforation + IAS stent4 (0.3)BPV + Rashkind3 (0.2)AD stent + RPA/LAP stent2 (0.1)BAV + Rashkind2 (0.1)BAV + AD stent2 (0.1)Rashkind + IAS stent2 (0.1)BAV + BPV1 (\<0.1)AD stent + Aorta PTA1 (\<0.1)APV perf + RPA/LAP PTA1 (\<0.1)MAPCAs embolization + AD embolization1 (\<0.1)BPV + AD stent + IVC PTA1 (\<0.1)IAS stent + AD stent1 (\<0.1)BPV + AD stent + Rashkind1 (\<0.1)Rashkind + Aorta PTA1 (\<0.1)BPV + BTV + AD stent1 (\<0.1)[^1]-the [Table 2](#tbl0002){ref-type="table"} labels the adverse events (either major or minor) listed in 8 categories: vascular access adverse events, arrhythmias, pericardial effusions, direct intra-cardiac lesions, great vessels damages, technical complications of the procedure, significant hemodynamic compromise and other adverse eventsTable 2Summary Adverse EventsTable 2Major and Minor Adverse EventsN (%)**Vascular Access Adverse Events21 (13.3)**Femoral Artery Pseudo-aneurysm3 (1.9)Femoral Artery Thrombosis12 (7.6)Femoral Vein Thrombosis6 (3.8)**Arrhythmias23 (14.6)**Brady-arrhythmia7 (4.4)Atrial Flutter7 (4.4)Supra-ventricular Tachycardia5 (3.2)Ventricular Fibrillation4 (2.5)**Pericardial Effusion38 (24.1)**Haematic Pericardial Effusion26 (16.5)Cardiac Tamponade12 (7.6)**Direct Intracardiac Lesions8 (5.1)**Ventricular Pseudo-aneurysm2 (1.3)Heart Perforation3 (1.9)Rope Rupture with severe TR1 (0.6)Intra-cardiac Thrombus2 (1.3)**Great Vessels Damage9 (5.6)**Aortic Dissection1 (0.6)RPA/LPA Stenosis3 (1.9)IVC/SVC Perforation2 (1.3)RPA Perforation1 (0.6)Acute SVC Thrombosis1 (0.6)SVC Thrombosis1 (0.6)**Technical Complications of Procedure9 (5.6)**Stent Embolization4 (2.5)Balloon Embolization1 (0.6)Stent Jailing1 (0.6)Acute Intra-stent Thrombosis3 (1.9)**Significant Hemodynamic Compromise26 (16.5)**Cardio-circulatory Arrest4 (2.5)Low-output Syndrome14 (8.9)Shock8 (5.1)**Others24 (15.2)**Pulmonary Embolism1 (0.6)Mild Haemorrhage2 (1.3)Transient Myocardial Ischemia6 (3.8)Cerebral Ischemia4 (2.5)Pneumothorax5 (3.2)Sepsis5 (3.2)Pleural Effusion1 (0.6)**Total Adverse Events158,00**[^2]-the [Table 3](#tbl0003){ref-type="table"} and the [Table 4](#tbl0004){ref-type="table"} show multi-variable analyses (binary logistic regression) of the potential risk factors (gender, low-weight, prematurity, genetic syndrome, uni-ventricular heart physiology, hybrid approach, risk category, age ≤7 days and procedure failure) and the major interventional procedures (arterial duct stenting, atretic pulmonary valve perforation, balloon aortic valvuloplasty, balloon pulmonary valvuloplasty, Rashkind atrioseptostomy) in terms of primary and secondary outcomesTable 3Multi-variable analysis of the potential risk factorsTable 3Binary logistic regression of the primary outcomesFAILUREMAEMORTALITYCOMPOSITE OUTCOMEWaldOR (95% CI)p-WaldOR (95% CI)p-WaldOR (95% CI)p-WaldOR (95% CI)p-**Gender**0.801.28 (0.75 -- 2.21)0.371.040.77 (0.46 -- 1.28)0.313.670.58 (0.33 -- 1.01)0.060.870.84 (0.58 -- 1.21)0.08**LW (≤2.5 kg)**1.201.48 (0.74 -- 2.96)0.275.051.99 (1.09 -- 3.61)0.0310.672.75 (1.50 -- 5.04)**\<0.01**9.111.96 (1.27 -- 3.04)**\<0.01Prematurity**0.060.88 (0.45 -- 3.35)0.810.231.22 (0.55 -- 2.71)0.639.413.09 (1.50 -- 6.34)**\<0.01**6.152.02 (1.16 -- 3.52)**\<0.01Genetic Syndromes**0.710.42 (0.54 -- 3.21)0.424.012.73 (1.02 -- 7.27)0.0520.867.88 (3.25 -- 19.12)**\<0.01**6.512.73 (1.26 -- 5.90)**\<0.01UVH**16.193.81 (1.99 -- 7.30)**\<0.01**0.551.30 (0.65 -- 2.60)0.4631.595.35 (2.98 -- 9.60)**\<0.01**32.943.78 (2.40 -- 5.96)**\<0.01Hybrid Approach**2.690.27 (0.06 -- 3.21)0.101.481.88 (0.68 -- 5.2)0.220.031.10 (0.38 -- 3.17)0.860.990.65 (0.28 -- 1.51)0.91**Risk Category**28.494.67 (2.65 -- 8.23)**\<0.01**14.942.80 (1.66 -- 4.72)**\<0.01**0.031.06 (0.60 -- 1.85)0.8639.223.22 (2.23 -- 4.64)**\<0.01Age ≤7 days**6.702.36 (1.23 -- 4.54)**\<0.01**1.391.39 (0.81 -- 2.39)0.240.110.91 (0.53 -- 1.58)0.746.921.70 (1.14 -- 2.53)**\<0.01Failure**\-\--36.757.79 (4.01 -- 15.12)**\<0.01**49.5313.20 (6.43 -- 27.07)**\<0.01**\-\--Binary logistic regression of the secondary outcomesBLOOD TRANSFUSIONMiAEWaldOR (95% CI)p-WaldOR (95% CI)p-**Gender**3.510.59 (0.33 -- 1.06)0.080.790.80 (0.50 -- 1.30)0.37**LW (≤2.5 kg)**6.402.28 (1.20 -- 4.30)**\<0.01**0.210.85 (0.43 -- 1.70)0.65**Prematurity**3.262.01 (0.94 -- 4.30)0.070.060.88 (0.32 -- 2.43)0.80**Genetic Syndromes**10.004.12 (1.71 -- 9.93)**\<0.01**0.011.04 (0.24 -- 4.52)0.96**UVH**0.010.98 (0.43 -- 2.21)0.951.140.59 (0.23 -- 1.55)0.29**Hybrid Approach**0.040.89 (0.26 -- 3.03)0.850.510.47 (0.06 -- 3.77)0.48**Risk Category**17.763.47 (1.94 -- 6.18)**\<0.01**3.321.57 (0.97 -- 2.56)0.07**Age ≤7 days**7.580.46 (0.27 -- 0.80)**\<0.01**0.131.10 (0.66 -- 1.83)0.72**Failure**5.362.90 (1.18 -- 7.16)0.021.021.66 (0.62 -- 4.40)0.31[^3]Table 4Multi-variable analysis of the major proceduresTable 4Binary logistic regression of the primary outcomesFAILUREMAEMORTALITYCOMPOSITE OUTCOMEWaldOR (95% CI)p-WaldOR (95% CI)p-WaldOR (95% CI)p-WaldOR (95% CI)p-**AD Stenting**0.160.74 (0.17 -- 3.18)0.697.713.87 (1.49 -- 10.07)**\<0.01**3.762.99 (0.99 -- 9.02)0.058.703.13 (1.47 -- 6.66)**\<0.01APV Perforation**14.4917.92 (4.05 -- 79.16)**\<0.01**9.635.56 (1.88 -- 16.43)**\<0.01**0.591.67 (0.45 -- 6.17)0.4420.517.21 (3.07 -- 16.95)**\<0.01BAV**1.683.10 (0.56 -- 17.12)0.28.735.71 (1.80 -- 18.15)**\<0.01**2.592.93 (0.79 -- 10.80)0.1111.424.84 (1.94 -- 12.09)**\<0.01BPV**0.010.93 (0.16 -- 5.35)0.930.730.56 (0.15 -- 2.12)0.393.410.19 (0.03 -- 1.10)0.061.030.60 (0.23 -- 1.61)0.31**Rashkind Atrio-septostomy**1.022.15 (0.48 -- 9.58)0.311.702.01 (0.7 -- 5.74)0.191.311.99 (0.61 -- 6.49)0.254.642.46 (1.08 -- 5.60)0.03Binary logistic regression of the secondary outcomesBLOOD TRANSFUSIONMiAEWaldOR (95% CI)p-WaldOR (95% CI)p-**AD Stenting**5.934.10 (1.31 -- 12.25)0.020.441.44 (0.49 -- 4.18)0.51**APV Perforation**0.271.42 (0.38 -- 5.30)0.63.383.06 (0.93 -- 10.10)0.07**BAV**2.853.05 (0.84 -- 11.09)0.091.750.30 (0.05 -- 1.79)0.19**BPV**0.001.01 (0.30 -- 3.38)1.00.351.43 (0.44 -- 4.66)0.55**Rashkind Atrio-septostomy**3.100.31 (0.08 -- 1.15)0.080.350.70 (0.21 -- 2.92)0.56[^4]-the [Table 5](#tbl0005){ref-type="table"} describes in each large column the multi-variable analysis (binary logistic regression) of the different potential risk factors in terms of composite outcome (in-hospital mortality, major adverse event and/or failure) of each major procedure, as individually analyzedTable 5Multi-variable analysis of the potential risk factors in the most common procedures and hybrid approachesTable 5Binary logistic regression of the composite outcome (failure and/or major adverse events and/or mortality)AD StentingAtretic Pulmonary Valve PerforationRashkind Atrio-septostomyBalloon Pulmonary ValvuloplastyWaldOR (95% CI)p-WaldOR (95% CI)p-WaldOR (95% CI)p-WaldOR (95% CI)p-**Gender**0.401.35 (0.54 -- 3.40)0.532.930.45 (0.18 -- 1.12)0.090.360.83 (0.45 -- 1.54)0.550.900.50 (0.12 -- 2.10)0.34**LW (≤2.5 kg)**1.391.95 (0.64 -- 5.92)0.245.463.46 (1.22 -- 9.80)0.021.351.56 (0.74 -- 3.33)0.250.932.27 (0.43 -- 12.06)0.34**Prematurity**0.141.32 (0.30 -- 5.85)0.710.081.22 (0.30 -- 4.98)0.786.083.23 (1.27 -- 8.22)0.021.623.50 (0.51 -- 24.08)0.20**Genetic Syndromes**7.725.24 (1.63 -- 16.83)**\<0.01**\-\--4.364.54 (1.10 -- 18.82)0.04\-\--**UVH**7.863.79 (1.49 -- 9.63)**\<0.01**\-\--21.664.71 (2.45 -- 9.05)**\<0.01**\-\--**Age ≤7 days**0.761.52 (0.59 -- 3.92)0.380.030.89 (0.25 -- 3.24)0.861.111.77 (0.61 -- 5.14)0.29\<0.011.03 (0.27 -- 3.97)0.97Balloon Aortic ValvuloplastyHybrid ApproachWaldOR (95% CI)p-WaldOR (95% CI)p-**Gender**2.972.58 (0.88 -- 7.58)0.090.190.62 (0.07 -- 5.25)0.66**LW (≤2.5 kg)**7.596.30 (1.70 -- 23.34)**\<0.01**0.021.15 (0.15 -- 8.86)0.90**Prematurity**0.290.66 (0.15 -- 3.01)0.590.071.44 (0.10 -- 21.88)0.79**Genetic Syndromes**\-\--2.5310.23 (0.58 -- 179.9)0.11**UVH**0.201.46 (0.27 -- 7.75)0.662.510.27 (0.05 -- 1.37)0.11**Age ≤7 days**4.864.21 (1.17 -- 15.12)0.032.894.16 (0.80 -- 21.52)0.09[^5]-the [Table 6](#tbl0006){ref-type="table"} compares the first and second half-time periods (2000-2008 vs 2009-2017) of our observational dataset in terms of demography, risk factors and interventional proceduresTable 6Comparison of temporal period (years 2000-2008 vs 2009-2017)Table 6Years 2000-2008Years 2009-2017p-valueTotal catheterizationN=528N=1023**Risk Factors and Demographic DataWeight (kg)**3.0±0.53.0±0.60.8**Prematurity**27 (5.1%)89 (8.7%)**\<0.01Genetic syndromes**6 (1.1%)34 (3.3%)**\<0.01UVH physiology**40 (7.8%)113 (11%)0.03**Hybrid Approach**2 (0.4%)40 (3.9%)**\<0.01Outcomes AnalysisComposite Outcomes**46 (8.7%)114 (11.1%)0.1**Failure**19 (4.2%)40 (3.9%)0.8**MAE**22 (4.2%)55 (5.4%)0.3**Mortality**20 (3.8%)60 (5.9%)0.08**MiAE**23 (4.4%)58 (5.7%)0.3**Blood transfusion**13 (2.5%)51 (5.0%)0.02**Total proceduresN=537N=1078AD stenting**9 (1.7%)173 (16.0%)**\<0.01APV perforation**49 (9.1%)77 (7.1%)0.2**BAV**51 (9.5%)84 (7.8%)0.2**BPV**116 (21.6%)238 (22.0%)0.8**Rashkind Atrio-septostomy**266 (49.5%)426 (39.5%)**\<0.01RVOT stenting**2 (0.4%)14 (1.3%)0.08[^6][^7]-the [Figure 1](#fig0001){ref-type="fig"} is the forest plots representation of multi-variable analysis of the potential risk factors (**A**) and the most performed procedures (**B**) on the primary outcomesFig. 1Forest plots reporting the effects of potential risk factors (**A**) and major procedures (**B**) on the primary outcomes.Fig 1-the [Figure 2](#fig0002){ref-type="fig"} shows, anonymously, the number of trans-catheter interventions for single centre (**A**) and, accordingly, the rate of composite outcome (**B**)Fig. 2Column graph of the number of interventional catheterizations (**A**) and the composite outcome rate (**B**) for any individual centre both as overall (**blue column**) and separated data ranked as lower (**orange column**) and higher (**grey column**) procedure risk. The box reported the p-value calculated by linear regression analysis test.Fig 2

2. Experimental Design, Materials, and Methods {#sec0002}
==============================================

In the related research article [@bib0001], a retrospective detection of all consecutive interventional cardiac catheterizations performed in neonatal age was carried out by the eight Italian higher-volume centres involved in the study (Bologna, Genoa, Massa, Milan, Naples, Padua, Rome and Turin). To achieve this dataset, hospital registry and clinical folders were examined. From January 2000 to December 2017, 1423 consecutive newborns were submitted to 1551 interventional cardiac catheterizations, during which 1615 interventions were performed. The term "catheterization" was used to indicate any procedural session, while the term "procedure" was used to report any specific intervention. Primary outcomes were any procedure-related major adverse event (MAE), in-hospital mortality and failure of the intended procedure. They were analyzed both individually and as a composite outcome. Secondary outcomes were any procedure-related minor adverse event (MiAE) and need for blood transfusion. Gender, low-weight, prematurity, genetic syndrome, uni-ventricular heart physiology, hybrid approach, risk category, age ≤7 days and failure were analyzed as potential risk factors.

Multi-variable analysis was performed with a binary logistic regression [@bib0002] and used to evaluate the independent impact of any risk factor on the outcome of interventional cardiac catheterization, either as a whole or for each specific procedure. Furthermore, the multi-variable analysis was used to evaluate the risk profile of the five more common procedures (arterial duct stenting, atretic pulmonary valve perforation, balloon aortic valvuloplasty, balloon pulmonary valvuloplasty, Rashkind atrio-septostomy) on short-term outcome.

The data reported in the [Table 6](#tbl0006){ref-type="table"}, comparing the first and the second half observational period were analysed by two-tail chi-square test (for categorical and binary variables) or unpaired two-samples Student\'s t-test (for continuous variables).

The data were then divided for any centre in order to evaluate, by linear regression test, the impact of the volume of activity of any individual centre on the composite outcome. The same statistical analysis was also made by separating the higher-risk procedures (risk category 4) from the lower ones (risk category 3) [@bib0003].

Appendix. Supplementary materials {#sec0004}
=================================
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[^1]: **AD**: Arterial Duct; **APV**: Atretic Pulmonary Valve; **BAV**: Balloon Aortic Valvuloplasty; **BPV**: Balloon Pulmonary Valvuloplasty; **BTV**: Balloon Tricuspid Valvuloplasty; **IAS**: InterAtrial Septum; **IVC**: Inferior Vena Cava; **LPA**: Left Pulmonary Artery; **MAPCA**: Major Aorto-Pulmonary Collateral Arteries; **PTA**: Percutaneous Trans-luminal Angioplasty; **PV**: Pulmonary Vein; **RPA**: Right Pulmonary Artery; **RVOT**: Right Ventricle Outflow Tract; **SVC**: Superior Vena Cava

[^2]: **IVC**: Inferior Vena Cava; **LPA**: Left Pulmonary Artery; **RPA**: Right Pulmonary Artery; **SVC**: Superior Vena Cava; **TR**: Tricuspid Regurgitation

[^3]: **Abbreviations. LW**: Low-Weight; **MAE**: Major Adverse Events; **MiAE**: Minor Adverse Events; **UVH**: Uni-Ventricular Heart

[^4]: **Abbreviations. AD**: Arterial Duct; **APV**: Atretic Pulmonary Valve; **BAV**: Balloon Aortic Valvuloplasty; **BPV**: Balloon Pulmonary Valvuloplasty; **MAE**: Major Adverse Events; **MiAE**: Minor Adverse Events

[^5]: **Abbreviations. LW**: Low-Weight; **UVH**: Uni-Ventricular Heart

[^6]: Continuous variables are expressed as mean±SD, whereas dichotomic variables as absolute values (percentage). Test T-Student and chi-square test were used to compare continuous and dichotomic variables, respectively.

[^7]: **Abbreviations. AD**: Arterial Duct; **APV**: Atretic Pulmonary Valve; **BAV**: Balloon Aortic Valvuloplasty; **BPV**: Balloon Pulmonary Valvuloplasty; **MAE**: Major Adverse Events; **MiAE**: Minor Adverse Events; **RVOT**: Right Ventricle Outflow Tract; **UVH**: UniVentricular Heart
